OTC · Healthcare
ALLURION TECHNOLOGIES, INC. (ALUR)
As-reported financials and recent SEC filings for ALLURION TECHNOLOGIES, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$15.2M
Net income
$-28.8M
Net margin
—
Diluted EPS
$-3.81
ROE
37.3%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|
| Revenue | $15.2M | $32.1M | $53.5M | $64.2M |
| Gross profit | $9.6M | $21.5M | $41.5M | $50.7M |
| Operating income | $-30.2M | $-50.2M | $-79.1M | $-32.0M |
| Net income | $-28.8M | $-7.2M | $-82.8M | $-37.7M |
| Diluted EPS | $-3.81 | $-1.07 | $-19.79 | $-12.58 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-30
View on EDGAR →8-K2026-06-17
View on EDGAR →8-K2026-05-27
View on EDGAR →10-Q2026-05-15
View on EDGAR →10-K2026-03-30
View on EDGAR →8-K2026-03-12
View on EDGAR →SCHEDULE 13D/A2026-03-02
View on EDGAR →8-K2026-03-02
View on EDGAR →Largest Healthcare peers
Go deeper on ALUR
Search ALLURION TECHNOLOGIES, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.